FDA Seeks Standardization For NGS Tumor Testing
This article was originally published in The Gray Sheet
Executive Summary
Without some standardization of cancer tumor tissue collection methods, sample enrichment, and synchronized sequencing criteria and platforms, next-generation sequencing tests could be of low quality for diagnoses, researchers cautioned at a recent FDA workshop. The agency is likely to develop a guidance to clarify best methods, an FDA official says.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.